Literature DB >> 10873867

Economic evaluation and end-stage renal disease: from basics to bedside.

B J Manns1, K J Taub, C Donaldson.   

Abstract

Economic evaluation is the comparative analysis of alternative health care interventions in terms of their relative costs (resource use) and effectiveness (health effects). High-quality studies of economic evaluation have been increasingly published in medical journals and read by clinicians, although publication of these studies in nephrology journals has been a more recent phenomenon. This article shows how the basic principles of economics can be applied to health care through the use of economic evaluation. Different types of economic evaluation are discussed, and pitfalls common to such studies are identified. A simple framework is introduced that can be used to interpret the results of economic evaluations. Using this framework, selected therapies for patients with end-stage renal disease (ESRD) are categorized to highlight therapies that are very efficient, encourage their use, and draw attention to therapies in current use that are less effective and more expensive (ie, less efficient) than alternative therapy. Using examples pertinent to care of the patient with ESRD, we show how economic evaluation can be used to link medical outcomes, quality of life, and costs in a common index for multiple therapies with disparate outcome measures. This article highlights the need for clinical studies and economic evaluations of therapies in ESRD for which the effects of the therapy on health outcomes and/or costs are unknown.

Entities:  

Mesh:

Year:  2000        PMID: 10873867     DOI: 10.1053/ajkd.2000.8235

Source DB:  PubMed          Journal:  Am J Kidney Dis        ISSN: 0272-6386            Impact factor:   8.860


  4 in total

1.  Continuous renal replacement therapy is associated with less chronic renal failure than intermittent haemodialysis after acute renal failure.

Authors:  Max Bell; Fredrik Granath; Staffan Schön; Anders Ekbom; Claes-Roland Martling
Journal:  Intensive Care Med       Date:  2007-03-16       Impact factor: 17.440

Review 2.  The economics of end-stage renal disease care in Canada: incentives and impact on delivery of care.

Authors:  Braden J Manns; David C Mendelssohn; Kenneth J Taub
Journal:  Int J Health Care Finance Econ       Date:  2007-09

3.  Alternative strategies to evaluate the cost-effectiveness of peritoneal dialysis and hemodialysis.

Authors:  Tapani Salonen; Tuomo Reina; Heikki Oksa; Pekka Rissanen; Amos Pasternack
Journal:  Int Urol Nephrol       Date:  2007-02-27       Impact factor: 2.266

Review 4.  Long-term outcome after intensive care: can we protect the kidney?

Authors:  Max Bell; Claes-Roland Martling
Journal:  Crit Care       Date:  2007       Impact factor: 9.097

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.